Showing 5171-5180 of 23238 results for "".
Predicting Breast Cancer Metastasis with Proteomics
https://reachmd.com/programs/project-oncology/predicting-breast-cancer-metastasis-with-proteomics/49189/Recognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
https://reachmd.com/programs/dermconsult/pso-hs-subset-genetic-risk/39676/Insights on PsA Management
https://reachmd.com/programs/practical-dermatology/insights-on-psa-management/23665/With about one-third of psoriasis patients likely to develop joint disease, dermatologists must be prepared to comanage PsA symptoms.Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
https://reachmd.com/cme/obesity/improvement-in-health-outcomes-with-glp-1ra-in-patients-with-overweight-or-obesity-with-cvd/17779/3' education - Nov. 11, 2023 - Ania Jastreboff, MD, PhDThe Difficult But Important Job of a Forensic Pathologist in the COVID-19 Pandemic
https://reachmd.com/programs/public-health-call/the-difficult-but-important-job-of-a-forensic-pathologist-in-the-covid-19-pandemic/11369/Tune in as a forensic pathologist explains the role of autopsies in the public health response to COVID-19.Reimagining Menopause with Hormones and Longevity
https://reachmd.com/ma-issues-index/jan-feb-2026-issue/reimagining-menopause-with-hormones-and-longevity/54435/ILD in Rheumatic Diseases: Evolving Management Strategies
https://reachmd.com/programs/living-rheum/ild-in-rheumatic-diseases-evolving-management-strategies/30074/Explore the latest recommendations and research on screening, diagnosing, and monitoring lung complications in autoimmune rheumatic diseases.Bridging the Gap to Improved Schizophrenia Treatment Options
https://reachmd.com/programs/neurofrontiers/bridging-the-gap-to-improved-schizophrenia-treatment-options/27072/Explore the connection between schizophrenia and substance abuse, and discover potential treatment pathways for optimal care.Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
https://reachmd.com/clinical-practice/dermatology/early-onset-of-response-to-zasocitinib-tak-279-a-highly-selective-and-potent-tyk2-inhibitor-is-correlated-with-modulation-of-tyk2-signaling-and-disease-pathway-biomarkers-in-patients-with-moderate-to-severe-plaque-psoriasis/50977/Review phase 2b trial data on zasocitinib in patients with moderate-to-severe plaque psoriasis.10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
https://reachmd.com/programs/project-oncology/portec-3-chemoradiotherapy-high-risk-endometrial-cancer/39928/